Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities

Size: px
Start display at page:

Download "Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities"

Transcription

1 Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities P. Peris 1, V. Ruiz-Esquide 1, A. Monegal 1, L. Alvarez 2, M.J. Martínez de Osaba 3, Á. Martínez-Ferrer 1, R. Reyes 1, N. Guañabens 1 Services of 1 Rheumatology and 2 Clinical Biochemistry, 3 Hormonal Laboratory, Hospital Clínic, University of Barcelona, Institut d Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Abstract Objective Osteoporosis is infrequent in young premenopausal women and is often associated with secondary disorders. However, idiopathic osteoporosis may be found in this setting and few data are known on this condition. Therefore, the aim of this study was to analyse the clinical characteristics and bone remodelling abnormalities in premenopausal women with idiopathic osteoporosis. Methods 28 premenopausal women with idiopathic osteoporosis (aged 38.3±7.6 years) were included. The patients had one or more fragility fractures and/or decreased bone mass (z-score <-2 in the lumbar spine or femur). In all patients, secondary causes of osteoporosis were excluded and previous skeletal fractures, family history and risk factors for osteoporosis were recorded. In addition, bone mineral density at the lumbar spine and hip, spinal x-rays, and laboratory tests including PTH, 25-hydroxyvitamin D, 1,25 (OH) 2 vitamin D and urinary calcium excretion were measured. Bone markers such as serum bone alkaline phosphatase (bone AP) and P1NP, and urinary hydroxyproline (HYP), NTx and CTx were measured and results were compared with those observed in a control group of 28 healthy premenopausal women. Results 46% of the patients had previous fragility fractures, 53% had family history of osteoporosis, 36% had associated hypercalciuria and 30% had a BMI <20 Kg/m 2. Patients with idiopathic osteoporosis had increased bone resorption markers (NTx and HYP) but normal bone formation markers when compared with healthy controls. No significant differences in the clinical and biochemical parameters were observed between patients with or without hypercalciuria. Conclusion Young women with idiopathic osteoporosis have an increased bone resorption without changes in bone formation when assessed by biochemical markers. Key words Primary osteoporosis, premenopausal osteoporosis, bone turnover, low bone mass, bone markers. Clinical and Experimental Rheumatology 2008; 26:

2 Pilar Peris, Virginia Ruiz-Esquide, Ana Monegal, Luisa Alvarez, M a Jesús Martínez de Osaba, Ángeles Martínez-Ferrer, Raquel Reyes, Nuria Guañabens. The study was supported by a grant from the Instituto de Salud Carlos III 03/08. Please address correspondence and reprint requests to: Pilar Peris, Servicio de Reumatología, Hospital Clínic, Villarroel 170, Barcelona, Spain ppb@comb.es Received on December 6, 2007; accepted in revised form on April 14, Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Competing interests: none declared. Introduction Osteoporosis is an uncommon disorder in young individuals. Nevertheless, because of the Gaussian distribution of bone mineral density (BMD) values, it could be expected that nearly 0.5% of this population would have low densitometric values, that is, a bone mass below 2.5 T-score (1). Indeed, in our country 0.34% of women aged 20 to 44 years have a lumbar T-score of-2.5 or less (2). In young individuals osteoporosis is frequently associated with secondary disorders. However, idiopathic disease is also a common cause of osteoporosis in these patients (3-6). Although little is known about this process it is likely that its pathogenesis is heterogeneous. In fact, findings such as low levels of IGF-I, increased interleukin 1, decreased β-estradiol levels, history of delayed puberty or an osteoblastic dysfunction, among others, have been reported (7-11). In addition, we have previously described some clinical characteristics in patients with idiopathic osteoporosis such as younger age, frequent association with hypercalciuria and family history of osteoporosis, the latter further suggesting a genetic role in some of these patients (3, 6). Moreover, few studies have focused on the characteristics of bone turnover in this process, and when assessed, they showed variable results. Thus, in some cases a decrease in bone formation parameters has been reported (9, 10, 12, 13), whereas in others an increase in bone resorption has been indicated (14). Therefore, the aim of this study was to analyse the clinical features and bone remodelling characteristics in premenopausal women with idiopathic osteoporosis. Patients and methods Twenty-eight premenopausal Caucasian women with idiopathic osteoporosis aged years (mean age±standard deviation (SD) 38.3±7.6 years) were included in the study. The patients had one or more fragility fractures and/or decreased bone mass, i.e., a Z-score <-2 in the lumbar spine or femur (15). In all patients secondary causes of osteoporosis were excluded and previous skeletal fractures, renal lithiasis, weight, height, body mass index (BMI), and family history of osteoporosis were recorded, as well as dietary calcium intake and current and past consumption of alcohol and tobacco. Daily dietary calcium intake was based on a food frequency questionnaire and alcohol consumption was recorded as number of drinks per week. No patient reported delayed menarche or menstrual irregularities. Standard radiographs of the spine were obtained in all patients to evaluate the presence of vertebral fractures as well as BMD measurements at the lumbar spine and femoral neck (Lunar DPX-L). The coefficients of variation were 0.8% and 2.3% for lumbar spine and femoral neck, respectively. Vertebral fracture was defined as a reduction 20% in the anterior, middle, or posterior height of the vertebral body when compared with the adjacent, undeformed vertebra. Idiopathic osteoporosis was diagnosed after excluding secondary causes for low bone mass and fragility fractures. Informed consent was obtained from all the subjects, and the study was approved by the Ethics Committee of the Hospital. Biochemical determinations and markers of bone turnover Blood and second morning urine samples were obtained between 8:00 and 10:00 a.m after an overnight fast. Automated biochemical profile and complete blood cell count were determined in all patients, as well as serum calcium, phosphate, 25-hydroxyvitamin D (25-OHD), 1,25-dyhydroxyvitamin D (1-25OH 2 D) and parathyroid hormone (PTH), and 24-hour urinary calcium excretion. Hypercalciuria was defined as a urinary calcium excretion >4mg/ kg/day. The bone formation markers measured were: serum bone alkaline phosphatase (bone AP) (Tandem-R Ostase; Beckman Coulter, Fullerton, CA, USA) and procollagen type I N propeptide (P1NP) (Intact PINP; Orion, Espoo, Finland). The markers of bone resorption measured were: N-terminal cross-linking telopeptide of type I collagen (NTx) and C-terminal cross-linking telopeptide (β-ctx), both measured in urine by enzyme immunoassays (Osteomark; 987

3 Ostex International Inc, Seattle, WA, USA and CrossLaps ELISA); and urinary hydroxyproline (HYP), which was measured by high-performance liquid chromatography. Urine determinations were expressed in relation to creatinine excretion. Reference values of markers of bone turnover were obtained from 28 healthy premenopausal women of similar ages (control group). Statistical analysis All data are expressed as mean±sd (standard deviation of the mean). To analyse differences between continuous variables, the Willcoxon test was used. Differences between proportions were assessed by the Chi square test. The Spearman s rank correlation test was used for correlation studies. A p-value of <0.05 was considered statistically significant. Results Fourteen patients (50%) had previous skeletal fractures (12 had peripheral fractures, 4 had vertebral fractures; 2 patients presented with both peripheral and vertebral fractures), 53% had family history of osteoporosis, 30% had a BMI <20 kg/m 2, 36% of the patients had associated hypercalciuria and 25% had previous renal lithiasis (most of these patients, 5 out of 7 (71%), had associated hypercalciuria). The clinical characteristics of the patients are shown in Table I. The mean calcium intake was 761.2±334 mg/day, but 35% of the patients had calcium intake lower than 500 mg/day, and only 39% of them had a dietary calcium intake higher than 1000 mg/day. Alcohol consumption was reported in 10% of the patients, but in all of them alcohol consumption was one drink or less per week. Eleven patients (39%) were smokers. Patients with idiopathic osteoporosis showed an increase in bone resorption markers with significantly higher urinary values of NTx (42.7±23 vs. 28.5±14.2 nm BCE/mM, p<0.05) and HYP (121.1±104 vs. 63.4±23 nmol/mg, p=0.007) when compared to controls (Table II and Fig. 1); conversely, urinary β-ctx (another bone resorption marker) and bone formation markers, Table I. Clinical characteristics of the patients. P1NP and bone AP, were similar to controls (Table II). When patients with idiopathic osteoporosis were compared according the presence or absence of hypercalciuria, no significant differences in the analysed clinical (BMI, family history of osteoporosis, skeletal fractures, calcium intake, renal lithiasis, lifestyle habits) and biochemical parameters (PTH, 25-OHD, 1-25 OHD, bone markers) were found between both groups of patients, except for a Patients with idiopathic osteoporosis n=28 Age (years) 38.3 ± 7.6 Age at menarche (years) 12.9 ± 1.3 BMI (kg/m 2 ) 21.7 ± 2.9 Weight (kg) 54.9 ± 9 Height (cm) 158,9 ± 7.6 Calcium intake (mg/day) ± 334 Family history of osteoporosis (%) 53 % Current smokers (%) 39 % Alcohol intake (%) 1 drink per day 10% >1 drink per day Renal lithiasis (%) 25 % Previous fracture (%) Any site 50 % Peripheral 43 % vertebrae 14 % Data are expressed as means±sd. BMI: body mass index. Table II. Bone mass, biochemical parameters and bone markers in women with idiopathic osteoporosis. Normal values Idiopathic OP With HYPC Without HYPC n=28 n=10 n=18 Lumbar Z-score ± ± ± 0.4 Femur Z-score ± ± ± 0.6 PTH pg/ml ± ± ± OHD ng/ml ± ± ± OHD pg/ml ± ± ± 16 Bone AP ng/ml 11.9 ± ± ± ± 8.5 P1NP ng/ml 30 ± ± ± ± 16.9 HYP nmol/mg 63.4 ± ± 104* ± 133* ± 92* NTx nm BCE/mM 28.5 ± ± 23* 51.6 ± 29* 36.1 ± 15 β-ctx mg/mm ± ± ± ± 80 Data are expressed as mean±sd *p<0.05 compared to control group. HYPC: hypercalciuria; 25-OHD: 25-hydroxyvitamin D; 1-25OH 2 D: 1.25-dyhydroxyvitamin D; PTH: parathyroid hormone; HYP: hydroxyproline; Bone AP: bone alkaline phosphatase; P1NP: procollagen type I N propeptide; NTx: N-terminal cross-linking telopeptide of type I collagen; β-ctx: C-terminal cross- linking telopeptide of type I collagen. higher urinary calcium excretion in hypercalciuric patients (147±56 vs. 276±63 mg/24h, p<0.001). Nor were significant differences observed in lumbar or femoral BMD between either group of patients. In addition, when patients with idiopathic osteoporosis were compared, classified according to the presence or absence of skeletal fractures, no significant differences in clinical, densitometric and biochemical parameters (including bone markers) 988

4 Fig. 1. Bone markers of bone turnover in patients and controls. The grey bars show the values of patients with idiopathic osteoporosis and the white bars show the values of controls. *p<0.05 patients vs. controls. For other abbreviations see Table II. Table III. Correlations between markers of bone turnover in women with idiopathic osteoporosis. were observed between either group of patients (Table II). When correlations among biochemical markers were evaluated, NTx and β-ctx were the only bone markers that showed a significant correlation (r=0.762, p=0.028) in women with idiopathic osteoporosis (Table III). Discussion This study shows that young women with idiopathic osteoporosis may present various clinical features, such as frequent family history of osteoporosis, low BMI and calcium intake and, in a subset of patients, hypercalciuria. In addition, the bone turnover in these patients is characterized by an increase in bone resorption markers. Idiopathic osteoporosis is a relatively P1NP Bone AP NTx β-ctx Bone AP (0.268) NTx (0.282) (0.223) β-ctx (0.243) (0.051) (0.002) HYP (0.474) (0.470) (0.410) (0.202) Spearman rank correlation coefficients. Significance level in parentheses. For other abbreviations see Table II. common cause of osteoporosis in young individuals, constituting in some series nearly 50% of the cases (2-6). However, although there are few studies focusing on the pathogenesis of this disorder, it is likely that there are various mechanisms related to this condition. Indeed, family history of osteoporosis was observed in more than 50% of our patients, and idiopathic hypercalcuria and low BMI were observed in more than 30% of them; Most of these findings have been previously described (3, 4, 16, 17). The strong family history of osteoporosis in premenopausal osteoporotic women provides further support for current theories of genetic predisposition to osteoporosis. Indeed, previous reports indicated a high frequency of low bone mass in the relatives of individuals with idiopatic osteoporosis (18, 19) and nearly 50% of young women with maternal history of osteoporosis had low bone mass (20). In addition, recent findings point towards a major contributory role of a genetically determined maturational defect in bone acquisition in the pathogenesis of idiopathic osteoporosis (21). Additional contributing factors, such as low calcium intake, tobacco consumption and low body weight, frequently observed in our patients, may favour the development of osteoporosis in these individuals. Thus, only 39% of the women in the present study had an acceptable dietary calcium intake, nearly 40% of them were current smokers and 30% had a BMI lower than 20. All these factors have been previously related to low bone mass and fractures in young premenopasual women (22-26). Hypercalciuria and renal lithiasis have also been associated with bone loss and osteoporosis in some, but not all studies (27-29). Although hypercalciuria could be considered as a secondary cause of osteoporosis, the mechanism of bone loss in this process is still unclear, this fact probably explains the inclusion of this disorder in the subgroup of patients with idiopathic disease (10, 30) and was the cause of the inclusion of these patients in our study. Thus, several factors may be involved in bone loss in idiopathic hypercalciuria, including increased prostaglandin E2 production, a negative calcium balance due to a reduction in renal tubular calcium resorption and an increased activity of cytokines, including tumour necrosis factor α, interleukin 1 and granulocyte macrophage stimulating factor (8, 31). The features of bone remodelling in idiopathic osteoporosis in previous studies are variable and mostly described in men, with some patients having evidence of a defect in osteoblast function, whereas others having increased bone resorption (9-14). Thus, studies including histomorphometric analysis showed heterogeneous findings with a predominance of impaired osteoblast function with low bone formation rate and increased eroded surface, both suggesting that these patients have uncoupling between resorption and formation. Because an increase in bone formation 989

5 would be expected, in order to balance increased bone resorption, these studies suggested that this would be indicative of an osteoblastic dysfunction (10, 13, 32). These results were similar in both genders (9, 12). When bone turnover markers have been analysed, either non significant changes (21, 33) or an increase in bone resorption have both been observed (7, 14). Similarly, in our patients we have observed an increase in bone resorption markers. Thus, patients with idiopathic osteoporosis showed increased NTx and HYP values when compared to controls. Conversely, bone formation markers, such as bone AP and P1NP, were similar to controls and no correlations were observed between bone formation and bone resorption markers, further suggesting that there is an imbalance in bone remodelling in these patients. In addition, we did not observe significant differences in bone markers when patients were analysed according to the presence of associated hypercalciuria or previous skeletal fractures. Interestingly, urinary β-ctx, another bone resorption marker, though positively correlated with NTx, was not increased in these patients. Although the reasons for such discrepancies are not completely known, the special characteristics of this marker may partly explain this finding. Thus, the type I collagen C-telopeptide, CTx, contains a site, the aspartic acid residue which is susceptible to undergoing a β-isomerization. This spontaneous nonenzimatic post-translational modification results in a structural perturbation of the peptide backbone, which is believed to be associated with the ageing of proteins. So, in healthy adults, the isomerization process seems to reach an equilibrium, and nearly 70% of the type I collagen molecules from normal bone are isomerized (34). However, in some clinical conditions such as growing children, fractures and Paget s disease among others, the nonisomerized (α- CTx) molecule is the predominant collagen form (34-37). We hypothesize that the age of our patients could have influenced these results. In fact, it is possible that in this group of patients, the determination of α-ctx instead of β-ctx could be more appropriate for evaluating bone resorption due to the younger age of patients and, consequently, of the bone. Indeed, premenopausal women have higher α-ctx/β- CTx ratios (>1) that postmenopusal women, who showed ratios below 1 (35, 38), and this ratio tends to be higher in younger people (36, 38). Unfortunately, we did not determine the urinary levels of α-ctx in order to confirm this hypothesis. Nevertheless, it should be noted that the reference values of bone markers from control premenopausal healthy women used in this study are very close to those recently reported in the same group of population (39), further supporting the value of our results. All these data indicate that the evaluation of bone turnover markers in premenopausal women with osteoporosis should be cautiously analysed taking into account the special characteristics of this population. In conclusion, bone turnover in young women with idiopathic osteoporosis is characterized by an increase in bone resorption. In this condition, associated factors such as family history of osteoporosis, hypercalciuria and low BMI are frequent. Acknowledgments We are grateful to Robert Nichols for reviewing the English in the manuscript. References 1. KANIS JA, DELMAS P, BURCKHARDT P, COOPER C, TORGERSON D: Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997; 7: DÍAZ CURIEL M, GARCÍA JJ, CARRASCO JL et al.: Prevalencia de osteoporosis determinada por densitometría en la población femenina española. Med Clin (Barc) 2001; 116: PERIS P, GUAÑABENS N, MARTÍNEZ DE OSA- BA MJ et al.: Clinical Characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum 2002; 32: MOREIRA KULAK CA, SCHUSSCHEIM DH, MCMAHON DJ et al.: Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract 2000; 6: KAUFMAN JM, JOHNELL O, ABADIE E et al.: Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000; 59: PERIS P, MARTÍNEZ MA, MONEGAL A et al.: Etiology and clinical characteristics of male osteoporosis: have they changed in the past few years? J Bone Miner Res 2006; 21 (Suppl. 1): S PIETSCHMANN P, KUDLACEK S, GRISAR J et al.: Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 2001; 31; GHAZALI A, FUENTES V, DESAINT C et al.: Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997; 82: JOHANSSON AG, ERIKSEN EF, LINDH E et al.: Reduced serum levels of growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodelling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab 1997; 82: KHOSLA S, LUFKIN EG, HODGSON SF, FRITZ- PATRICK LA, MELTON LJ 3RD: Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15: CALÒ L, CASTRIGNANO R, DAVIS PA et al.: Role of insulin-like growth factor-i in primary osteoporosis: a correlative study. J Endocrinol Invest 2000; 23: CIRIA-RECASENS M, PEREZ-EDO L, BLANCH- RUBIO J et al.: Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone 2005; 36: DONOVAN MA, DEMPSTER D, ZHOU H, MC- MAHON DJ, FLEISHER J, SHANE E: Low bone formation in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2005; 90: RUBIN MR, SCHUSSHEIM DH, KULAK CAM et al.: Idiopathic osteoporosis in premenopausal women. Osteoporos Int 2005; 16: LEIB ES, LEWIECKI EM, BINKLEY N, HAMDY RC: Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7: PERIS P, GUAÑABENS N, MONEGAL A et al.: Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol 1995; 34: GOURLAY ML, BROWN SA: Clinical considerations in premenopausal osteoporosis. Arch Intern Med 2004; 164: COHEN-SOLAL ME, BAUDOIN C, OMOURI M, KUNTZ D, DE VERNEJOUL MC: Bone mass in middle-aged osteoporotic men and their relatives: familial effect. J Bone Miner Res 1998; 13: ERBAS B, RISTEVSKI S, POON C, YEUNG S, EBELING PR: Decreased spinal and femoral neck volumetric bone mineral density (BMD) in men with primary osteoporosis and their first-degree male relatives: familial effect on BMD in men. Clin Endocrinol 2007; 66: DANIELSON ME, CAULAY JA, BAKER CE et al.: Familiar resemblance of bone mineral density (BMD) and calcaneal ultrasound attenuation: the BMD in mothers and daughters study. J Bone Miner Res 1999; 14: VAN POTTELBERGH I, GOEMAERE S, ZMIERCZAK H, DE BACQUER D, KAUFMAN JM: Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation 990

6 family study. J Bone Miner Res 2003; 18: MEIN AL, BRIFFA NK, DHALIWAL SS, PRINCE R: Lifestyle influences on 9-year changes in BMD in young women. J Bone Miner Res 2004; 19: LLOYD T, ANDON M, ROLLINGS N et al.: Calcium supplementation and bone mineral density in adolescent girls. JAMA 1993; 270: BARAN D, SORENSEN A, GRIMES J et al.: Dietary modification with dairy products for preventing vertebral bone loss in premenopausal women: a three-year prospective study. J Clin Endocrinol Metab 1990; 70: BLUMM M, HARRIS SS, MUST A, PHIL- LIPS SM, RAND WM, DAWSON-HUGHES B: Weight and body mass index at menarche are associated with premenopausal bone mass. Osteoporos Int 2001; 12: HAWKER GA, JAMAL SA, RIDOUT R, CHASE C: A clinical prediction rule to identify premenopausal women with low bone mass. Osteoporos Int 2002; 13: HELLER HJ, ZERWEKH JE, GOTTSCHALK FA, PAK CYC: Reduced bone formation and relatively increased bone resorption in absortive hypercalciuria. Kidney Int 2007; 71: GARCÍA-NIETO V, NAVARRO JF, MONGE M, GARCÍA RODRÍGUEZ VE: Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephon Clin Pract 2003; 94: c CAUDARELLA R, VESCINI F, BUFFA A et al.: Bone mass loss in calcium stone disease: Focus on hypercalciuria and metabolic factors. J Nephrol 2003; 16: JP BILEZIKIAN, ES KURLAND, CJ ROSEN: Idiopathic osteoporosis in men. In ES ORWOLL (Ed.) Osteoporosis in men. The effects of gender on skeletal health. Academic Press, San Diego 1999, PACIFICI R: Idiopathic hyercalciuria and osteoporosis-distinct clinical manifestations of increased cytokine-induced bone resorption? J Clin Endocrinol Metab 1997; 82: PERNOW Y, GRANBERG B, SÄÄF M, WEIDEN- HIELM L: Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int 2006; 78: LORMEAU C, SOUDAN B, D HERBOMEZ M, PIGNY P, DUQUESNOY B, CORTET B: Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone 2004; FLEDELIUS C, JOHNSEN AH, CLOOS PAC, BONDE M, QVIST P: Characterization of urinary degradation products derived from type I collagen. J Biol Chem 1997; 272; PERIS P, ALVAREZ L, MONEGAL A et al.: Effects of surgical menopause and Paget s disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresoptive therapy. J Bone Miner Metab 2002; 20: DE LA PIEDRA C, CALERO JA, TRABA ML, ASENSIO MD, ARGENTE J, MUÑOS MT: Urinary α and β C-telopepetides of collagen I: clinical implications in bone remodeling in patients with anorexia nervosa. Osteoporos Int 1999; 10: ALEXANDERSEN P, PERIS P, GUAÑABENS N et al.: Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget s disease of bone. J Bone Miner Res 2005; 20: HOSHINO H, TAKAHASHI M, KUSHIDA K, OHISHI T, INOUE T: The relationships between the degree of β-isomerization of type I collagen degradation products in urine and aging, menopause and osteoporosis with fractures. Osteoporos Int 1999; 9: DE PAPP AE, BONE HG, CAULFIELD MP, KAGAN R, BUINEWICZ A, CHEN E: A crosssectional study of bone turnover markers in healthy premenopausal women. Bone 2007; 40:

Factors related to bone forming inadequate response to treatment (teriparatide/pth 1-84) in patients with severe osteoporosis. Preliminary results

Factors related to bone forming inadequate response to treatment (teriparatide/pth 1-84) in patients with severe osteoporosis. Preliminary results ORIGINALS / Rev Osteoporos Metab Miner 2015 7;4:85-90 85 Gifre L 1, Monegal A 1, Filella X 2, Muxi A 3, Guañabens N 1, Peris P 1 1 Unidad de Patología Metabólica Ósea - Servicio de Reumatología - Hospital

More information

Elecsys bone marker panel. Optimal patient management starts in the laboratory

Elecsys bone marker panel. Optimal patient management starts in the laboratory bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic

More information

BMD: A Continuum of Risk WHO Bone Density Criteria

BMD: A Continuum of Risk WHO Bone Density Criteria Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris

More information

Clinician s Guide to Prevention and Treatment of Osteoporosis

Clinician s Guide to Prevention and Treatment of Osteoporosis Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening

More information

Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date

Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date MP 2.04.10 Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013

More information

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover Last Review Status/Date: December 2014 Page: 1 of 12 Management of Osteoporosis and Diseases Description Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially

More information

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:

More information

Disclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis

Disclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest

More information

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular

More information

Study of secondary causes of male osteoporosis

Study of secondary causes of male osteoporosis Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos

More information

The Role of the Laboratory in Metabolic Bone Disease

The Role of the Laboratory in Metabolic Bone Disease The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology

More information

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone

More information

Forteo (teriparatide) Prior Authorization Program Summary

Forteo (teriparatide) Prior Authorization Program Summary Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis

More information

Low bone mass is a well-recognized complication of

Low bone mass is a well-recognized complication of GASTROENTEROLOGY 2010;138:2348 2356 Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis NÚRIA GUAÑABENS,*, DACIA CERDÁ,* ANA MONEGAL,* FRANCESCA PONS,*

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition

Index. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis

Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric

More information

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr. Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many

More information

The Skeletal Response to Aging: There s No Bones About It!

The Skeletal Response to Aging: There s No Bones About It! The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium

More information

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover Last Review Status/Date: March 2017 Page: 1 of 12 Management of Osteoporosis and Diseases Description Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially

More information

Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India

Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India International Journal of Public Health Science (IJPHS) Vol.3, No.4, December 2014, pp. 276 ~ 280 ISSN: 2252-8806 276 Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): July 10, 2002 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Αίηια ανδρικής οζηεοπόρωζης - Βιβλιογραθικές πηγές

Αίηια ανδρικής οζηεοπόρωζης - Βιβλιογραθικές πηγές Αίηια ανδρικής οζηεοπόρωζης - Βιβλιογραθικές πηγές 1. National Osteoporosis Foundation. Clinician s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation,

More information

PART FOUR. Metabolism and Nutrition

PART FOUR. Metabolism and Nutrition PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy

More information

An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines

An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines Osteoporos Int (2006) 17: 1111 1115 DOI 10.1007/s00198-006-0101-6 SHORT COMMUNICATION An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines R. Baddoura. H. Awada. J. Okais.

More information

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical

More information

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra

More information

Coordinator of Post Professional Programs Texas Woman's University 1

Coordinator of Post Professional Programs Texas Woman's University 1 OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic

More information

Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover

Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Medical Policy Manual Laboratory, Policy No. 23 Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Next Review: June 2018 Last Review: July

More information

European Journal of Endocrinology (1997) ISSN

European Journal of Endocrinology (1997) ISSN European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing

More information

Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome

Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented

More information

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with

More information

OSTEOPOROSIS CURRENTLY AFFECTS approximately

OSTEOPOROSIS CURRENTLY AFFECTS approximately 0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(6):3331 3336 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-2042 Low Bone Formation in Premenopausal

More information

Bone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases

Bone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral

More information

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008 BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology

More information

Correlation between Thyroid Function and Bone Mineral Density in Elderly People

Correlation between Thyroid Function and Bone Mineral Density in Elderly People IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini

More information

DM and Osteoporosis. Why is it important?

DM and Osteoporosis. Why is it important? DM and Osteoporosis Why is it important? Diabetes Osteoporosis Fractures Dr Pedro Conthe HGUGM Madrid Spain Agenda: DM and Osteoporosis Observational studies Physiopathology of bone Type I and Type 2 DM

More information

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment OPEN Citation: Bone Research (2017) 5, 17021; doi:10.1038/boneres.2017.21 www.nature.com/boneres ARTICLE Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment

More information

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012 Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco

More information

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into

More information

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)

More information

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org

More information

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department

More information

Zinc Intake and Biochemical Markers of Bone Turnover in Type 1 Diabetes

Zinc Intake and Biochemical Markers of Bone Turnover in Type 1 Diabetes Diabetes Care Publish Ahead of Print, published online September 22, 2008 Zinc and bone markers Zinc Intake and Biochemical Markers of Bone Turnover in Type 1 Diabetes Raelene E. Maser, PhD 1,2; John N.

More information

Clinical Evaluation of the Elecsys -CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides

Clinical Evaluation of the Elecsys -CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides Clinical Chemistry 47:8 1410 1414 (2001) Enzymes and Protein Markers Clinical Evaluation of the Elecsys -CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides Reiko

More information

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved

More information

Purpose. Methods and Materials

Purpose. Methods and Materials Prevalence of pitfalls in previous dual energy X-ray absorptiometry (DXA) scans according to technical manuals and International Society for Clinical Densitometry. Poster No.: P-0046 Congress: ESSR 2014

More information

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security

More information

Men and Osteoporosis So you think that it can t happen to you

Men and Osteoporosis So you think that it can t happen to you Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School

More information

Building Bone Density-Research Issues

Building Bone Density-Research Issues Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis

More information

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime

Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy

More information

Osteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?

Osteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made? A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.

More information

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et

More information

Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis

Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis Ulster Med J 2013;82(2):89-93 Paper Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis Thomas McNeilly, Colette McNally, Michael Finch, Timothy Beringer

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

Southern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism

Southern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or

More information

Supplemental tables: Abbreviations:

Supplemental tables: Abbreviations: Supplemental tables: Abbreviations: Osteoprotegerin (OPG), Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL), fibroblast growth factor-23 (FGF-23), C-terminal cross-linked telopeptide of type-i

More information

The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial

The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial Osteoporos Int () 4:87 877 DOI.7/s98-87-5 ORIGINAL ARTICLE The efficacy of calcium supplementation alone in elderly Thai women over a -year period: a randomized controlled trial R. Rajatanavin & L. Chailurkit

More information

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014 HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research

More information

Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women

Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women 727 REVIEW Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women E Dogan, C Posaci... Biochemical markers of bone metabolism are divided into two groups:

More information

Annie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu

Annie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and

More information

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11. NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk

More information

High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker

High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium Excretion and Bone Resorption Marker J Bone Metab 214;21:189-194 http://dx.doi.org/1.115/jbm.214.21.3.189 pissn 2287-6375 eissn 2287-729 Original Article High Dietary Sodium Intake Assessed by 24-hour Urine Specimen Increase Urinary Calcium

More information

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one

More information

Original Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT

Original Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone

More information

Because the low bone mass and deterioration

Because the low bone mass and deterioration OSTEOPOROSIS A look at recent expert guidelines and key studies in bone health, the findings of which affect your patients young and old Steven R. Goldstein, MD Dr. Goldstein is Professor of Obstetrics

More information

Immunodiagnostic Systems

Immunodiagnostic Systems Immunodiagnostic Systems Manual Immunoassay Product Menu www.idsplc.com Vitamin D 25-Hydroxy Vitamin D EIA Enzymeimmunoassay for the quantitative IVD AC-57F1 96 Wells determination of 25-hydroxyvitamin

More information

Immunoassays. EIA & RIA Product Portfolio. Commitment to innovation

Immunoassays. EIA & RIA Product Portfolio. Commitment to innovation Immunoassays EIA & RIA Portfolio Commitment to innovation info@idsplc.com www.idsplc.com Expertise in Endocrinology Diagnostics Immunodiagnostic Systems Limited is a leading in vitro diagnostic solutions

More information

Journal of Hainan Medical University. Wei Li. 1. Introduction. 28 Journal of Hainan Medical University 2016; 22(21): 28-32

Journal of Hainan Medical University. Wei Li. 1. Introduction. 28 Journal of Hainan Medical University 2016; 22(21): 28-32 28 Journal of Hainan Medical University 2016; 22(21): 28-32 Journal of Hainan Medical University http://www.hnykdxxb.com Dual-energy X-ray absorptiometry assessment of postmenopausal women with vertebral

More information

THE DIAGNOSIS OF OSTEOPOROSIS BY MEASURING LUMBAR VERTEBRAE DENSITY WITH MDCT: A COMPARATIVE STUDY WITH QUANTITATIVE COMPUTERIZED TOMOGRAPHY (QCT)

THE DIAGNOSIS OF OSTEOPOROSIS BY MEASURING LUMBAR VERTEBRAE DENSITY WITH MDCT: A COMPARATIVE STUDY WITH QUANTITATIVE COMPUTERIZED TOMOGRAPHY (QCT) Acta Medica Mediterranea, 2013, 29: 775 THE DIAGNOSIS OF OSTEOPOROSIS BY MEASURING LUMBAR VERTEBRAE DENSITY WITH MDCT: A COMPARATIVE STUDY WITH QUANTITATIVE COMPUTERIZED TOMOGRAPHY (QCT) KEMAL KARA 1,

More information

original Se Hwa Kim 1), Tae Ho Kim 1) and Soo-Kyung Kim 2)

original Se Hwa Kim 1), Tae Ho Kim 1) and Soo-Kyung Kim 2) Endocrine Journal 2014, 61 (12), 1197-1204 original Effect of high parathyroid hormone level on bone mineral density in a vitamin D-sufficient population: Korea National Health and Nutrition Examination

More information

Male osteoporosis: clinical approach and management in family practice

Male osteoporosis: clinical approach and management in family practice Singapore Med J 2014; 55(7): 353-357 doi: 10.11622/smedj.2014085 CMEArticle Male osteoporosis: clinical approach and management in family practice Lay Hoon Goh 1,2, MMed, FCFP, Choon How How 1, MMed, FCFP,

More information

Biochemistry #02. The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami. 0 P a g e

Biochemistry #02. The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami. 0 P a g e ]Type text[ ]Type text[ ]Type text[ Biochemistry #02 The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami 0 P a g e Greetings everyone, ladies and gentlemen The biochemical

More information

HAART HIV & BONE METABOLISM HAART EDITORIAL. Bologna, April 5 th, 2013

HAART HIV & BONE METABOLISM HAART EDITORIAL. Bologna, April 5 th, 2013 HIV correlated pathologies and other infections HIV & BONE METABOLISM Bologna, April 5 th, 2013 Morning Session: Davide Gibellini, Fabio Vescini, Paolo Bonfanti, Stefano Mora, Antonio Di Biagio, Tiziana

More information

Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism

Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed

More information

What Is FRAX & How Can I Use It?

What Is FRAX & How Can I Use It? What Is FRAX & How Can I Use It? Jacqueline Osborne PT, DPT Board Certified Geriatric Clinical Specialist Certified Exercise Expert for the Aging Adult Brooks Rehabilitation; Jacksonville, FL Florida Physical

More information

Screening points for a peripheral densitometer of the calcaneum for the diagnosis of osteoporosis

Screening points for a peripheral densitometer of the calcaneum for the diagnosis of osteoporosis 23 Ivorra Cortés J, Román-Ivorra JA, Alegre Sancho JJ, Beltrán Catalán E, Chalmeta Verdejo I, Fernández-Llanio Comella N, Muñoz Gil S Servicio de Reumatología - Hospital Universitario Dr. Peset - Valencia

More information

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis

More information

Differentiating Pharmacological Therapies for Osteoporosis

Differentiating Pharmacological Therapies for Osteoporosis Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking

More information

Osteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals. Susan J Whiting University of Saskatchewan

Osteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals. Susan J Whiting University of Saskatchewan Osteoporosis and Nutrition Module 4 Speaking of Bones Osteoporosis For Health Professionals Susan J Whiting University of Saskatchewan Learning Objectives Understand the 3 critical nutrients for bone:

More information

Osteoporosis is a frequent complication in

Osteoporosis is a frequent complication in Randomized Trial Comparing Monthly Ibandronate and Weekly Alendronate for Osteoporosis in Patients With Primary Biliary Cirrhosis Nuria Gua~nabens, 1,2 Anna Monegal, 1 Dacia Cerda, 1 Africa Muxı, 3 Laia

More information

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1 Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,

More information

Management of postmenopausal osteoporosis

Management of postmenopausal osteoporosis Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,

More information

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Update. Greg Summers Consultant Rheumatologist Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o

More information

A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman

A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome

More information

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.

More information

Alendronate sodium in the management of osteoporosis

Alendronate sodium in the management of osteoporosis REVIEW Alendronate sodium in the management of osteoporosis P J J Prinsloo 1 D J Hosking 2 1 Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2 Dept Endocrinology and Diabetes, City Hospital,

More information

Valen&na Morelli, Cris&na Eller-Vainicher, Iacopo Chiodini,

Valen&na Morelli, Cris&na Eller-Vainicher, Iacopo Chiodini, PROPOSAL: Study on the effect of the shi6 from classic glucocor

More information

Chapter 39: Exercise prescription in those with osteoporosis

Chapter 39: Exercise prescription in those with osteoporosis Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:

More information

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC. Focus on CME at the University of Western Ontario Osteoporosis: Not Just for Women Anymore By Lisanne G. Laurier, MD, PhD, FRCPC Osteoporosis is characterized by low bone mass and microarchitectural deterioration

More information

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development

More information

Clinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with vertebral fracture

Clinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with vertebral fracture Osteoporos Int (2011) 22:667 674 DOI 10.1007/s00198-010-1260-z ORIGINAL ARTICLE Clinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with

More information

Collagen Crosslinks, Any Method

Collagen Crosslinks, Any Method 190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement

More information

Current and Emerging Strategies for Osteoporosis

Current and Emerging Strategies for Osteoporosis Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis

More information

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page f #3 Awaisheh Abdullah Alaraj Mousa Al-Abbadi 1 Page *This sheet was written from Section 1 s lecture, in the first 10 mins the Dr. repeated all the previous material relating to osteoporosis from the

More information

AGENDA. Risk factors for fracture in diabetes:

AGENDA. Risk factors for fracture in diabetes: AGENDA Risk factors for fracture in diabetes: - Who has to be screened? - How to screen? BMD AND FRACTURES IN TYPE 2 DIABETES Vestergaard P, Osteoporos Int 2007 3 USEFULNESS OF FRAX ALGORYTHM IN TYPE 2

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information